Financial Performance - For the nine months ended September 30, 2020, the group achieved a consolidated revenue of RMB 251,610,019, a decrease of 11.56% compared to RMB 284,484,546 for the same period last year[4] - The consolidated gross profit for the same period was RMB 23,175,044, down 24.87% from RMB 30,848,000 year-on-year[4] - The loss attributable to equity holders of the company was RMB 15,911,732, an increase of 12.38% from a loss of RMB 14,158,779 in the previous year[4] - The basic loss per share for the nine months was RMB 0.839, compared to RMB 0.75 for the same period last year[5] - The group reported a pre-tax loss of RMB 16,295,575 for the nine months, compared to a loss of RMB 13,584,656 in the previous year[5] - The income tax expense for the nine months was RMB 361,014, compared to an income tax credit of RMB 36,006 in the previous year[11] - The consolidated gross profit for the same period was RMB 23,175,044, down 24.87% from RMB 30,848,000 in 2019, resulting in a gross profit margin of 9.21%, a decline of 1.64% year-on-year[19] - The sales and distribution costs increased by 6.72% to RMB 14,377,707 from RMB 13,472,729 in the previous year[19] - Research and administrative expenses decreased by 24.13% to RMB 22,011,858 compared to RMB 29,011,540 in 2019[19] - Financing costs significantly reduced by 60.74% to RMB 979,196 from RMB 2,494,206 in the previous year[19] Dividend and Shareholder Information - The company did not recommend the payment of any dividend for the nine months ended September 30, 2020[5] - The company does not recommend the payment of an interim dividend for the nine months ended September 30, 2020, compared to no dividend in the same period of 2019[15] - As of September 30, 2020, the company’s major shareholders include Tianjin TEDA International Entrepreneurship Center with 182,500,000 shares (9.63%) and Shenzhen Xiangyong Investment Co., Ltd. with 180,000,000 shares (9.50%)[27] Business Operations and Strategy - The company is actively expanding its composite fertilizer business and focusing on the elderly care and health services sector, particularly for the disabled and dementia patients[18] - The company anticipates an increase in fertilizer demand due to rising prices of agricultural products and the recovery of the composite fertilizer industry[22] - The company aims to enhance the management level of integrated medical and elderly care institutions, aligning with national policies and social economic development trends[23] - The EEG detection business has faced slow development due to various factors, including the impact of the COVID-19 pandemic, but the company is working to expand this business as a profit growth point[23] - The company is actively working to build an integrated medical and elderly care industry platform to enhance its core competitiveness in this field[23] - The company’s EEG detection technology is noted for its advanced technical capabilities and market applicability, indicating potential for future growth[23] Financial Guarantees and Liabilities - The contingent liabilities related to bank loans provided as guarantees amounted to RMB 9,893,750 as of September 30, 2020, down from RMB 15,000,000 at the end of 2019[20] - The company has a profit guarantee agreement with SJKGC, which stipulates a minimum audited after-tax profit of $5,390,000 for the fiscal years 2017, 2018, and 2019[29] - For the fiscal year ending December 31, 2017, SJKGC reported an audited after-tax profit of approximately $2,922,000, failing to meet the profit guarantee[30] - For the fiscal years ending December 31, 2018 and 2019, SJKGC reported after-tax profits of $305,000 and $411,000 respectively, both below the guaranteed amount[31] - The arbitration process regarding the profit guarantee with SJK is ongoing, initiated on September 3, 2019[31] Corporate Governance - The company has adhered to the corporate governance code, except for the requirement that the roles of chairman and CEO should be separate[37] - The current CEO also serves as the chairman, which the board believes is in the company's best interest for maintaining policy continuity and operational stability[38] - The company is actively seeking candidates for the CEO position to comply with corporate governance transparency and independence[38] - The audit committee has reviewed the group's financial reporting procedures for the nine months ending September 30, 2020[33] - No new share option plans were approved during the period ending September 30, 2020[34] - The company did not enter into any management contracts for overall business or any major business during the period ending September 30, 2020[35] - There were no repurchases of shares during the review period, and the company or its subsidiaries did not buy, sell, or redeem any shares during the period ending September 30, 2020[36] Reporting and Transparency - The report will be available on the GEM website and the company's website for at least seven days from the publication date[40]
泰达生物(08189) - 2020 Q3 - 季度财报